IFNL4 and hepatitis C virus infection: Although IFNL4 polymorphisms are important predicators of hepatitis C cure with interferon-based therapies, newer DAA therapies are interferon-free, and as such IFNL4 polymorphism assessment will not be as useful in countries where only DAAs are being used to treat HCV [14,15].